

Supplementary Materials

**Induction of endoplasmic reticulum stress-mediated apoptosis by aminosteroid RM-581
efficiently blocks the growth of PC-3 docetaxel-resistant prostate cancer cells and tumors**

René Maltais¹, Jenny Roy¹, Martin Perreault¹, Sachiko Sato², Julie-Christine Lévesque², and Donald Poirier^{1,3,*}

¹ *Laboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Québec Research Center, Québec, QC, G1V 4G2, Canada.*

² *Bioimaging platform, CHUL-CHU de Québec Research Centre, Faculty of Medicine, Laval University, Québec, QC, G1V 4G2, Canada.*

³ *Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada.*

Supplementary Materials

Table of contents.....	1
Table S1. Calculated physicochemical and ADME properties of RM-581-Fluo.....	2
Table S2. Calculated physicochemical and ADME properties of RM-581	3
Table S3. List of fatty acids dosed in PC-3 tumors.....	4
Table S4. Primer sequences.....	6
Figure S1. Cell proliferation and EC ₅₀ values in LNCaP (A), DU-145 (B) and PC-3 (C) cells treated with RM-581	7
Figure S2. Emission spectra of RM-581-Fluo at different pH and concentrations	8
Figure S3. Three additional confocal imaging pictures from a second experiment with RM-581-Fluo in PC-3 cells	10
Figure S4. Cell proliferation and EC ₅₀ values after continuous exposure to RM-581 in PC-3 cells	13

Table S1. Calculated physicochemical and ADME properties of RM-581-Fluo

[<http://www.swissadme.ch/faq.php>]. Copyright [2021] [SwissADME].




Table S2. Calculated physicochemical and ADME properties of RM-581

[<http://www.swissadme.ch/faq.php>]. Copyright [2021] [SwissADME].

Molecule 1			
		SIZE	Water Solubility
			Log S (ESOL) ⓘ -7.38
		Solubility	2.70e-05 mg/ml ; 4.17e-08 mol/l
		Class ⓘ	Poorly soluble
		Log S (Ali) ⓘ -7.42	
		Solubility	2.45e-05 mg/ml ; 3.79e-08 mol/l
		Class ⓘ	Poorly soluble
		Log S (SILICOS-IT) ⓘ -8.10	
		Solubility	5.13e-06 mg/ml ; 7.93e-09 mol/l
		Class ⓘ	Poorly soluble
		Pharmacokinetics	
		GI absorption ⓘ	High
		BBB permeant ⓘ	No
		P-gp substrate ⓘ	No
		CYP1A2 inhibitor ⓘ	No
		CYP2C19 inhibitor ⓘ	Yes
		CYP2C9 inhibitor ⓘ	No
		CYP2D6 inhibitor ⓘ	No
		CYP3A4 inhibitor ⓘ	Yes
		Log K_p (skin permeation) ⓘ	-6.10 cm/s
		Druglikeness	
		Lipinski ⓘ	Yes; 1 violation: MW>500
		Ghose ⓘ	No; 3 violations: MW>480, MR>130, #atoms>70
		Veber ⓘ	Yes
		Egan ⓘ	Yes
		Muegge ⓘ	No; 3 violations: MW>600, XLOGP3>5, #rings>7
		Bioavailability Score ⓘ	0.55
		Medicinal Chemistry	
		PAINS ⓘ	0 alert
		Brenk ⓘ	1 alert: triple_bond ⓘ
		Leadlikeness ⓘ	No; 2 violations: MW>350, XLOGP3>3.5
		Synthetic accessibility ⓘ	5.92

Table S3. List of fatty acids dosed in human PC-3 tumors

		CTL group (PC-3 tumor)		RM-581 (PC-3 tumor)	
Fatty acids (FA)	Common name	%	mg FA/g of tissue	%	mg FA/g of tissue
C8:0		0.00	0.00	0.00	0.00
C10:0		0.00	0.00	0.00	0.00
C12:0		0.17	0.03	0.15	0.02
14:0	Myristic acid	1.48	0.22	1.35	0.16
9t-14:1 n5		0.00	0.00	0.00	0.00
9c-14:1 n5	Myristoleic acid	0.15	0.02	0.12	0.01
C15:0		0.15	0.02	0.17	0.02
C16:0 DMA		0.00	0.00	0.04	0.01
C15:1 n5t		0.17	0.03	0.19	0.02
C15:1 n5c		0.00	0.00	0.00	0.00
C15:1 n1c		0.00	0.00	0.00	0.00
16:0	Palmitic acid	19.59	2.98	18.71	2.22
9t-16:1 n7	Palmitelaidic acid	0.00	0.00	0.00	0.00
C17:0 isobranched		0.00	0.00	0.00	0.00
9c-16:1 n7	Palmitoleic acid	9.87	1.50	6.96	0.83
C18:0 DMA		0.00	0.00	0.00	0.00
C17:1 n7t		0.12	0.02	0.13	0.02
C18:1 DMA		0.18	0.03	0.20	0.02
C17:1 n7c		0.00	0.00	0.00	0.00
18:0	Stearic acid	2.77	0.42	3.30	0.39
6t-18:1 n12	Petroselaidic acid	0.00	0.00	0.00	0.00
9t-18:1 n9	Elaidic acid	0.01	0.00	0.00	0.00
11t-18:1 n7	Transvaccenic acid	0.07	0.01	0.13	0.02
7c-18:1 n11/6c-18:1 n12	/Petroselinic acid	0.00	0.00	0.00	0.00
9c-18:1 n9	Oleic acid	31.44	4.78	30.38	3.61
11c-18:1 n7	Vaccenic acid	2.05	0.31	2.05	0.24
12c-18:1 n6		0.00	0.00	0.00	0.00
13c-18:1 n5		0.03	0.00	0.03	0.00
9t12t-18:2 n6	Linolelaidic acid	0.00	0.00	0.00	0.00
9c12t-18:2 n6		0.09	0.01	0.11	0.01
9t12c-18:2 n6		0.00	0.00	0.00	0.00
9c12c-18:2 n6 (LA)	Linoleic acid	26.27	3.99	28.90	3.44
9t12t15t-18:3 n3		0.06	0.01	0.04	0.00
20:0	Arachidic acid	0.19	0.03	0.25	0.03
6c9c12c-18:3 n6	gamma-Linolenic acid	0.06	0.01	0.06	0.01
9c12c15c-18:3 n3 (ALA)	alpha-Linolenic acid	1.18	0.18	1.25	0.15
8c-20:1 n12		0.00	0.00	0.00	0.00
11c-20:1 n9	Gondoic acid	0.58	0.09	0.61	0.07

6c9c12c15c- 18:4 n3	Stearidonic acid	0.04	0.01	0.04	0.00
11c14c- 20:2 n6		0.31	0.05	0.48	0.06
22:0	Behenic acid	0.08	0.01	0.09	0.01
8c11c14c- 20:3 n6	Dihomo-gamma-linolenic acid	0.47	0.07	0.76	0.09
C22:1 n9t		0.00	0.00	0.00	0.00
11c14c17c- 20:3 n3 (ETE)		0.02	0.00	0.03	0.00
5c8c11c14c- 20:4 n6 (AA)	Arachidonic acid	0.71	0.11	1.04	0.12
13c- 22:1 n9	Erucic acid	0.07	0.01	0.08	0.01
8c11c14c17c- 20:4 n3 (ETA)		0.01	0.00	0.04	0.00
13c16c- 22:2 n6		0.03	0.00	0.05	0.01
5c8c11c14c17c- 20:5 n3 (EPA)	Timnodonic acid	0.02	0.00	0.02	0.00
24:0	Lignoceric acid	0.30	0.05	0.32	0.04
13c16c19c- 22:3 n3		0.00	0.00	0.00	0.00
15c- 24:1 n9	Nervonic acid	0.05	0.01	0.06	0.01
7c10c13c16c- 22:4 n6	Adrenic acid	0.54	0.08	0.82	0.10
4c7c10cx13c16c- 22:5 n6	Adrenic acid	0.14	0.02	0.20	0.02
7c10c13c16c19c- 22:5 n3 (DPA)		0.15	0.02	0.22	0.03
4c7c10c13c16c19c- 22:6 n3 (DHA)	Cervonic acid	0.37	0.06	0.58	0.07
Total		100.00	15.20	100.00	11.89

n-3/n-6 (0,20 à 0,33)
n-6 total
n-3 total

0.06	0.06	0.07	0.07
28.63	4.35	32.42	3.85
1.81	0.28	2.18	0.26

Saturated
P (n-3 & 6)/S
Polyunsaturated n3 cis
Polyunsaturated n6 cis
Polyunsaturated n3 trans
Polyunsaturated n6 trans

24.73	3.76	24.40	2.90
1.23	1.23	1.42	1.42
1.75	0.27	2.14	0.25
28.52	4.33	32.29	3.84
0.06	0.01	0.04	0.00
0.09	0.01	0.11	0.01
0.37	0.06	0.44	0.05

Monounsaturated trans
Monounsaturated cis
Monounsaturated n6 cis

44.24	6.72	40.29	4.79
0.00	0.00	0.00	0.00
0.52	0.08	0.60	0.07
74.57	11.33	74.77	8.89

Total trans
Total cis


28.54	4.34	32.31	3.84
-------	------	-------	------

Table S4. Primer sequences


	Forward sequence	Reverse sequence
HMGCR	TTCGGTGGCCTCTAGTGAGA	AAAGCTTCATTCAAGCCTGTCA
FASN	ATGGAGGAGGTGGTGATTGC	CTGGGCCCTCTGAAGTCGAA
BIP	CTTGGTATTGAAACTGTGGGAGGTG	TTCCAGTCAGATCAAATGTACCCAG
CHOP	GGAGGAGCCAGAACCAAGCAGA	TTCCGTTCCCTGGTTCTCCCTT
HERP	TGCATCAGGGCTTTGTTCC	AACCACTTGAGGAGCAGCATTCT

Figure S1. Cell proliferation and EC₅₀ values in LNCaP (**A**), DU-145 (**B**) and PC-3 (**C**) cells treated with RM-581. EC₅₀ values of 1.2, 4.4 and 1.2 μ M were obtained for LNCaP, DU-145 and PC-3 cells, respectively.

A) LNCaP Cells



B) DU-145 Cells



C) PC-3 Cells






Figure S2. Emission spectra of RM-581-Fluo at different pH and concentrations


a) Phosphate buffer, pH 7.5, RM-581-Fluo (50 μ M), Excitation 405 nm




b) Phosphate buffer only, pH 7.5, Excitation 405 nm




c) Phosphate buffer, pH 6.5, RM-581-Fluo (50 μ M), Excitation 405 nm



d) Phosphate buffer, pH 5.5, RM-581-Fluo (50 μ M), Excitation 405 nm



e) Phosphate buffer, pH 7.5, RM-581-Fluo (30 μ M), Excitation 405 nm



f) Phosphate buffer, pH 7.5, RM-581-Fluo (5 μ M), Excitation 405 nm




Figure S3. Three additional confocal imaging pictures from a second experiment with RM-581-Fluo in PC-3 cells. PC-3 cells were treated 2 h with 15 μ M of RM-581-Fluo prior microscopy. (A) Cellular localization of RM-581-Fluo in blue ($\lambda_{\text{ex}} 405 \text{ nm}$, $\lambda_{\text{em}} 460/50 \text{ nm}$); (B) Cellular localization of RM-581-Fluo in green ($\lambda_{\text{ex}} 405 \text{ nm}$, $\lambda_{\text{em}} 525/50 \text{ nm}$); (C) Cellular localization of ER-Tracker in red ($\lambda_{\text{ex}} 561 \text{ nm}$, $\lambda_{\text{em}} 593/40 \text{ nm}$); (D) Cellular localization of Cell-mask in cyan ($\lambda_{\text{ex}} 642 \text{ nm}$, $\lambda_{\text{em}} 700/75 \text{ nm}$); (E) Merged images A, C and D showing the localization of RM-581-Fluo (in blue), ER tracker (in red) and Cell-mask (in cyan); (F) Merged images B, C and D showing the localization of RM-581-Fluo (in green), ER tracker (in red), Cell-mask (in cyan) and a co-localization in yellow of RM-581-Fluo and ER-Tracker. Scale bar: 10 μm .




Figure S3 (follow)




Figure S3 (follow)






Figure S4. Cell proliferation and EC₅₀ values after continuous exposure to RM-581 in PC-3 cells. PC-3 cells did not develop resistance when treated with 0.8 μ M of RM-581. Cell proliferation and EC₅₀ values after 0 (**A**), 12 (**B**), 49 (**C**) and 119 (**D**) days of treatment with RM-581. EC₅₀ values are not significantly different.


A (EC₅₀ = 1.2 ± 0.8 μ M)



B (EC₅₀ = 1.1 ± 0.5 μ M)



C (EC₅₀ = 1.6 ± 0.6 μ M)



D (EC₅₀ = 0.8 ± 0.4 μ M)

